Michele Bottosso , Renata L. Sandoval , Benjamin Verret , Natalia Polidorio , Olivier Caron , Alessandra Gennari , Brittany L. Bychkovsky , Sophie H. Cahill , Maria I. Achatz , Valentina Guarneri , Fabrice André , Judy E. Garber
{"title":"乳腺癌合并Li-Fraumeni综合征患者的HER2水平及新辅助抗HER2治疗的疗效[J].中华肿瘤杂志,2011(11):114307。","authors":"Michele Bottosso , Renata L. Sandoval , Benjamin Verret , Natalia Polidorio , Olivier Caron , Alessandra Gennari , Brittany L. Bychkovsky , Sophie H. Cahill , Maria I. Achatz , Valentina Guarneri , Fabrice André , Judy E. Garber","doi":"10.1016/j.ejca.2025.115370","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115370"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome” [Eur J Cancer 211 (2024) 114307]\",\"authors\":\"Michele Bottosso , Renata L. Sandoval , Benjamin Verret , Natalia Polidorio , Olivier Caron , Alessandra Gennari , Brittany L. Bychkovsky , Sophie H. Cahill , Maria I. Achatz , Valentina Guarneri , Fabrice André , Judy E. Garber\",\"doi\":\"10.1016/j.ejca.2025.115370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"220 \",\"pages\":\"Article 115370\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804925001510\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001510","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to “HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome” [Eur J Cancer 211 (2024) 114307]
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.